PillRx only · Aerosol, Foam · Topical
Tazarotene
Brands: Fabior · Tazarotene
1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US2 NDCs
1 active makers
1 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 1 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$12.323
Latest avg · Jun 17, 2026
-1%
Since Dec 17, 2025
1
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
143
Rx · 2026 Q1
8.0K
Units dispensed
-76%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it1 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Mayne Pharma Inc. | unknown | 2 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Mar 21, 2018RECALLRecall (Class III): Fabior (tazarotene) Foam, 0.1%, 100 grams can, Rx only, Distributed by: Mayne Pharma, Greenville, NC 27834; NDC 51862-2…
Superpotent Drug: High out of specification results for tazarotene assay at the 9-month stability time point. — Recalling firm: Mayne Pharma Inc — Nationwide in the USA